Atara Biotherapeutics 向 FDA 提交了 ATA3219 的 IND 申请，ATA3219 是一种针对狼疮性肾炎的抗 CD19 CAR-T 疗法。 Atara Biotherapeutics submitted an IND application to the FDA for ATA3219, an anti-CD19 CAR-T therapy targeting lupus nephritis.

Atara Biotherapeutics 已向 FDA 提交了 ATA3219 的 IND 申请，ATA3219 是一种同种异体抗 CD19 CAR T 细胞疗法。 Atara Biotherapeutics has submitted an IND application to the FDA for ATA3219, an allogeneic anti-CD19 CAR T-cell therapy. 该疗法针对 CD19+ B 细胞，旨在解决狼疮性肾炎 (LN) 的根本原因，狼疮性肾炎是一种治疗选择有限的慢性疾病。 The therapy targets CD19+ B cells and aims to address the root cause of lupus nephritis (LN), a chronic disease with limited treatment options. 这是继 2023 年第三季度收到首次非霍奇金淋巴瘤 (NHL) 批准后，ATA3219 的第二次 IND 提交。 This is the second IND submission for ATA3219, following the first clearance received for non-Hodgkin's lymphoma (NHL) in Q3 2023.